Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT
We aimed to compare outcomes following treosulfan (TREO) or busulfan (BU) conditioning in a large cohort of myelofibrosis (MF) patients from the EBMT registry. A total of 530 patients were included; 73 received TREO and 457 BU (BU ≤ 6.4 mg/kg in 134, considered RIC, BU > 6.4 mg/kg in 323 consider...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
15 March 2024
|
| In: |
Bone marrow transplantation
Year: 2024, Jahrgang: 59, Heft: 7, Pages: 928-935 |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/s41409-024-02269-4 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41409-024-02269-4 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41409-024-02269-4 
|
| Verfasserangaben: | Marie Robin, Simona Iacobelli, Linda Koster, Jakob Passweg, Daniele Avenoso, Keith M.O. Wilson, Urpu Salmenniemi, Peter Dreger, Peter von dem Borne, John A. Snowden, Stephen Robinson, Maria Chiara Finazzi, Thomas Schroeder, Matthew Collin, Matthias Eder, Edouard Forcade, Michael Loschi, Stefania Bramanti, Jose Antonio Pérez-Simón, Tomasz Czerw, Nicola Polverelli, Joanna Drozd-Sokolowska, Kavita Raj, Juan Carlos Hernández-Boluda and Donal P. McLornan |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1902525604 | ||
| 003 | DE-627 | ||
| 005 | 20251127232551.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240913s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41409-024-02269-4 |2 doi | |
| 035 | |a (DE-627)1902525604 | ||
| 035 | |a (DE-599)KXP1902525604 | ||
| 035 | |a (OCoLC)1475311726 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Robin, Marie |e VerfasserIn |0 (DE-588)1162362154 |0 (DE-627)1026030668 |0 (DE-576)507384253 |4 aut | |
| 245 | 1 | 0 | |a Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis |b a registry-based study from the Chronic Malignancies Working Party of the EBMT |c Marie Robin, Simona Iacobelli, Linda Koster, Jakob Passweg, Daniele Avenoso, Keith M.O. Wilson, Urpu Salmenniemi, Peter Dreger, Peter von dem Borne, John A. Snowden, Stephen Robinson, Maria Chiara Finazzi, Thomas Schroeder, Matthew Collin, Matthias Eder, Edouard Forcade, Michael Loschi, Stefania Bramanti, Jose Antonio Pérez-Simón, Tomasz Czerw, Nicola Polverelli, Joanna Drozd-Sokolowska, Kavita Raj, Juan Carlos Hernández-Boluda and Donal P. McLornan |
| 264 | 1 | |c 15 March 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 13.09.2024 | ||
| 520 | |a We aimed to compare outcomes following treosulfan (TREO) or busulfan (BU) conditioning in a large cohort of myelofibrosis (MF) patients from the EBMT registry. A total of 530 patients were included; 73 received TREO and 457 BU (BU ≤ 6.4 mg/kg in 134, considered RIC, BU > 6.4 mg/kg in 323 considered higher dose (HD)). Groups were compared using adjusted Cox models. Cumulative incidences of engraftment and acute GVHD were similar across the 3 groups. The TREO group had significantly better OS than BU-HD (HR:0.61, 95% CI: 0.39-0.93) and a trend towards better OS over BU-RIC (HR: 0.66, 95% CI: 0.41-1.05). Moreover, the TREO cohort had a significantly better Progression-Free-Survival (PFS) than both the BU-HD (HR: 0.57, 95% CI: 0.38-0.84) and BU-RIC (HR: 0.60, 95% CI: 0.39-0.91) cohorts, which had similar PFS estimates. Non-relapse mortality (NRM) was reduced in the TREO and BU-RIC cohorts (HR: 0.44, 95% CI: 0.24-0.80 TREO vs BU-HD; HR: 0.54, 95% CI: 0.28-1.04 TREO vs BU-RIC). Of note, relapse risk did not significantly differ across the three groups. In summary, within the limits of a registry-based study, TREO conditioning may improve PFS in MF HSCT and have lower NRM than BU-HD with a similar relapse risk to BU-RIC. Prospective studies are needed to confirm these findings. | ||
| 650 | 4 | |a Cancer immunotherapy | |
| 650 | 4 | |a Diseases | |
| 650 | 4 | |a Stem-cell research | |
| 700 | 1 | |a Iacobelli, Simona |e VerfasserIn |4 aut | |
| 700 | 1 | |a Koster, Linda |e VerfasserIn |4 aut | |
| 700 | 1 | |8 1\p |a Passweg, Jakob R. |d 1959- |e VerfasserIn |0 (DE-588)1077588011 |0 (DE-627)837268265 |0 (DE-576)446392251 |4 aut | |
| 700 | 1 | |a Avenoso, Daniele |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wilson, Keith M. O. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Salmenniemi, Urpu |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 700 | 1 | |a von dem Borne, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |8 2\p |a Snowden, John A. |e VerfasserIn |0 (DE-588)1260198251 |0 (DE-627)1938456084 |4 aut | |
| 700 | 1 | |a Robinson, Stephen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Finazzi, Maria Chiara |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schroeder, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Collin, Matthew |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eder, Matthias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Forcade, Edouard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loschi, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bramanti, Stefania |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pérez-Simón, Jose Antonio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Czerw, Tomasz |e VerfasserIn |4 aut | |
| 700 | 1 | |8 3\p |a Polverelli, Nicola |e VerfasserIn |0 (DE-588)1337896381 |0 (DE-627)1897722028 |4 aut | |
| 700 | 1 | |a Drozd-Sokolowska, Joanna |e VerfasserIn |4 aut | |
| 700 | 1 | |8 4\p |a Raj, Kavita |e VerfasserIn |0 (DE-588)1308920849 |0 (DE-627)1869506685 |4 aut | |
| 700 | 1 | |a Hernández-Boluda, Juan Carlos |e VerfasserIn |4 aut | |
| 700 | 1 | |8 5\p |a McLornan, Donal |e VerfasserIn |0 (DE-588)1337879401 |0 (DE-627)1897714637 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bone marrow transplantation |d London : Springer Nature, 1997 |g 59(2024), 7, Seite 928-935 |h Online-Ressource |w (DE-627)320433366 |w (DE-600)2004030-1 |w (DE-576)091012996 |x 1476-5365 |7 nnas |a Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis a registry-based study from the Chronic Malignancies Working Party of the EBMT |
| 773 | 1 | 8 | |g volume:59 |g year:2024 |g number:7 |g pages:928-935 |g extent:8 |a Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis a registry-based study from the Chronic Malignancies Working Party of the EBMT |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41409-024-02269-4 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41409-024-02269-4 |x Verlag |z lizenzpflichtig |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 2\p |a cgwrk |d 20251101 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 3\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 4\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 5\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20240913 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 8 | ||
| 999 | |a KXP-PPN1902525604 |e 4579384946 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"noteIll":"Illustrationen","extent":"8 S."}],"id":{"doi":["10.1038/s41409-024-02269-4"],"eki":["1902525604"]},"relHost":[{"pubHistory":["Nachgewiesen 19.1997 -"],"title":[{"title":"Bone marrow transplantation","title_sort":"Bone marrow transplantation"}],"language":["eng"],"part":{"pages":"928-935","extent":"8","issue":"7","volume":"59","year":"2024","text":"59(2024), 7, Seite 928-935"},"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"320433366","origin":[{"publisherPlace":"London ; Basingstoke ; London","publisher":"Springer Nature ; Macmillan ; Nature Publishing Group","dateIssuedDisp":"1997-","dateIssuedKey":"1997"}],"disp":"Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis a registry-based study from the Chronic Malignancies Working Party of the EBMTBone marrow transplantation","physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2004030-1"],"issn":["1476-5365"],"eki":["320433366"]},"note":["Gesehen am 17.01.25"]}],"note":["Gesehen am 13.09.2024"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1902525604","origin":[{"dateIssuedDisp":"15 March 2024","dateIssuedKey":"2024"}],"person":[{"family":"Robin","display":"Robin, Marie","role":"aut","given":"Marie"},{"role":"aut","given":"Simona","display":"Iacobelli, Simona","family":"Iacobelli"},{"display":"Koster, Linda","role":"aut","given":"Linda","family":"Koster"},{"display":"Passweg, Jakob R.","given":"Jakob R.","role":"aut","family":"Passweg"},{"role":"aut","given":"Daniele","display":"Avenoso, Daniele","family":"Avenoso"},{"family":"Wilson","display":"Wilson, Keith M. O.","role":"aut","given":"Keith M. O."},{"given":"Urpu","role":"aut","display":"Salmenniemi, Urpu","family":"Salmenniemi"},{"family":"Dreger","role":"aut","given":"Peter","display":"Dreger, Peter"},{"role":"aut","given":"Peter","display":"von dem Borne, Peter","family":"von dem Borne"},{"family":"Snowden","display":"Snowden, John A.","role":"aut","given":"John A."},{"family":"Robinson","display":"Robinson, Stephen","given":"Stephen","role":"aut"},{"family":"Finazzi","role":"aut","given":"Maria Chiara","display":"Finazzi, Maria Chiara"},{"given":"Thomas","role":"aut","display":"Schroeder, Thomas","family":"Schroeder"},{"family":"Collin","display":"Collin, Matthew","given":"Matthew","role":"aut"},{"family":"Eder","display":"Eder, Matthias","role":"aut","given":"Matthias"},{"family":"Forcade","display":"Forcade, Edouard","role":"aut","given":"Edouard"},{"family":"Loschi","display":"Loschi, Michael","given":"Michael","role":"aut"},{"family":"Bramanti","role":"aut","given":"Stefania","display":"Bramanti, Stefania"},{"display":"Pérez-Simón, Jose Antonio","role":"aut","given":"Jose Antonio","family":"Pérez-Simón"},{"role":"aut","given":"Tomasz","display":"Czerw, Tomasz","family":"Czerw"},{"family":"Polverelli","role":"aut","given":"Nicola","display":"Polverelli, Nicola"},{"family":"Drozd-Sokolowska","display":"Drozd-Sokolowska, Joanna","given":"Joanna","role":"aut"},{"family":"Raj","role":"aut","given":"Kavita","display":"Raj, Kavita"},{"display":"Hernández-Boluda, Juan Carlos","role":"aut","given":"Juan Carlos","family":"Hernández-Boluda"},{"family":"McLornan","given":"Donal","role":"aut","display":"McLornan, Donal"}],"name":{"displayForm":["Marie Robin, Simona Iacobelli, Linda Koster, Jakob Passweg, Daniele Avenoso, Keith M.O. Wilson, Urpu Salmenniemi, Peter Dreger, Peter von dem Borne, John A. Snowden, Stephen Robinson, Maria Chiara Finazzi, Thomas Schroeder, Matthew Collin, Matthias Eder, Edouard Forcade, Michael Loschi, Stefania Bramanti, Jose Antonio Pérez-Simón, Tomasz Czerw, Nicola Polverelli, Joanna Drozd-Sokolowska, Kavita Raj, Juan Carlos Hernández-Boluda and Donal P. McLornan"]},"title":[{"title_sort":"Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis","title":"Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis","subtitle":"a registry-based study from the Chronic Malignancies Working Party of the EBMT"}],"language":["eng"]} | ||
| SRT | |a ROBINMARIETREOSULFAN1520 | ||